摘要
将66例因使用胰岛素增敏剂以外的口服降糖药血糖控制效果不佳而改为单独应用胰岛素的T2DM患者随机分为胰岛素组和胰岛素加罗格列酮(Ins+RSG)组,各33例。本研究共观察14周,并记录开始和结束时的胰岛素用量和低血糖发生情况,测HbA1c水平。Ins+RSG组观察结束时胰岛素用量比单用胰岛素组减少21%,HbA1c水平和低血糖不良反应发生次数均低于单用胰岛素组,体重差别无统计学意义。
Sixty-sixT2DM patients were randomly divided into 2groups：insulin group（n=33） and insulin plus rosiglitazone group（n=33）.Insulin dosage, HbAlc,body weight and hypoglycemia episode were recorded at beginning and at the end of trial.In result, insulin dosage was lower in insulin plus rosiglitazone group than in insulin group.So were the parameter of HbAlc level and hypoglycemic episode.
出处
《当代医学》
2011年第26期133-133,共1页
Contemporary Medicine
